Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Vitamin D May Lessen Age-related Cognitive Decline
Eating fish long considered "brain food" may really be good for the old grey matter, as is a healthy dose of sunshine, new research suggests.

New Hope For Patients With Melanoma - The Most Deadly Form Of Skin Cancer And The Most Rapidly Increasing Cancer In The UK
Roche and Plexxikon announced interim results from a phase I study with PLX4032 (R7204) a new, highly selective and potentially promising oral treatment for patients with advanced melanoma whose cancer harbours the BRAF mutation (known as mutation-positive). Patients treated with PLX4032 lived for a median of six months without their disease getting worse and more than half experienced significant shrinkage of their tumours; this included patients where the cancer had spread to the liver, lung and bone.1 Historically, less than 5% of metastatic melanoma patients are still alive five years after diagnosis.2
News of the day
NIST Researchers 'All Aglow' Over New Test Of Toxin Strength
A new National Institute of Standards and Technology (NIST) assay using a "glow or no glow" technique may soon help the U.S. Department of Homeland Security (DHS) defend the nation against a spectrum of biological weapons that could be used in a terrorist attack. One very dangerous toxin on the list is ricin, a protein derived from castor beans that is lethal in doses as small as 500 micrograms - about the size of a grain of salt.
Diagnostics

Merck Issues Statement On WHO Study Showing First Evidence That Elimination Of River Blindness Is Feasible In Africa

Merck & Co., Inc. issued the following statement in response to study results published today by the World Health Organization offering the first evidence that elimination of the tropical disease river blindness (onchocerciasis) in Africa is feasible with treatment with ivermectin (registered trademark Mectizan®). As the discoverer and manufacturer of Mectizan, Merck decided in 1987 to donate the drug to all who need it for as long as necessary until river blindness is eliminated as a public health problem. The Merck Mectizan Donation Program is one of the longest-running disease-specific drug donation and public/private partnership programs in history. "When Merck made the decision more than 20 years ago to donate Mectizan to help fight river blindness, we dreamed that a milestone like this might some day be possible," said Richard T. Clark, chairman, president and CEO, Merck & Co., Inc. "It gives me and thousands of Merck employees and retirees enormous satisfaction and pride to know we are playing a role in eliminating a dreaded disease that has ravaged villages and millions of people and generations of families." Since the program"s inception, Merck has donated 2.5 billion tablets of Mectizan at an estimated value of $3.75 billion. Recently, Merck pledged up to $25 million in support of an initiative with the World Bank, the World Health Organization and other partners to eliminate the disease in Africa. The Mectizan Donation Program now reaches more than 80 million people in Africa, Latin America and Yemen annually. For more information about the Merck Mectizan Donation Program and Merck"s corporate responsibility efforts, visit here. Merck


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009